Advice for Enhancing the Client–Sponsor Relationship - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Advice for Enhancing the Client–Sponsor Relationship
Key talks from the recent PDA/FDA regulatory conference highlight room for improvement.

Pharmaceutical Technology
Volume 36, Issue 11, pp. 76,78-79

Allan Coukell, director of the Medical Programs Pew Health Group at The Pew Charitable Trusts, provided a global perspective on this issue. He pointed out that outsourcing has grown exponentially over the past 10 years, complicating the already complicated pharmaceutical supply chain. In discussing this complexity, he brought to light some disturbing facts, including that FDA 483 observations to contract manufacturers have risen over the past three years. In addition, Coukell noted that "FDA has expressed concerns about deficiencies in supplier qualification programs and quality agreements and that current regulations do not require companies to assess supplier plants before purchasing ingredients from them, or to visit the plants at any time to ensure quality standards are in place." He further highlighted the steps being taken to address this gap in regulations through the passage of new laws such as the 2012 FDA Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendment (GDUFA). He also complimented industry on some of its initiatives aimed at resolving supply-chain issues, including the efforts of Rx-360 (the international pharmaceutical supply chain consortium), EXCiPACT (a voluntary international scheme to provide independent third-party certification of manufacturers, suppliers, and distributors of pharmaceutical excipients worldwide), and International Pharmaceutical Excipient Auditing (IPEA), which also provides third-party audits through a shared audit program and ANSI accredited certification program.

It is important for industry to understand and work to improve their client–service provider relationships. Such re-evaluations make both sponsors and CMOs more effective in achieving the goal of improving public health and safety.

Susan J. Schniepp is vice-president of Quality and Regulatory Affairs at Allergy Laboratories, Oklahoma City, OK 73109. Tel. 405.235.1451,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here